Last reviewed · How we verify
Tedizolid Phophate
Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit.
Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit. Used for Acute bacterial skin and skin structure infections (ABSSSI).
At a glance
| Generic name | Tedizolid Phophate |
|---|---|
| Also known as | TR701-122, MK-1986, SIVEXTRO® |
| Sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | oxazolidinone antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Tedizolid phosphate works by binding to the 50S ribosomal subunit of bacteria, which prevents the formation of the 70S initiation complex and thereby inhibits protein synthesis. This action is bacteriostatic, meaning it prevents the growth and replication of bacteria, rather than killing them outright. As a result, tedizolid phosphate is effective against a wide range of Gram-positive bacteria, including MRSA.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
Key clinical trials
- Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis (PHASE4)
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: